# Servier

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/servier/

## Facts

| Field | Value |
| --- | --- |
| Country | FR |
| Description | French pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320327235 |
| ROR ID | https://ror.org/034e7c066 |
| Works | 19,083 |

## Funder papers

Showing 15 of 23.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial](https://scholariq.org/papers/patiromer-for-the-management-of-hyperkalemia-in-heart-failure-with-reduced/)
- [Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study](https://scholariq.org/papers/substance-use-disorders-in-adolescents-with-attention-deficit-hyperactivity/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease](https://scholariq.org/papers/efficacy-and-safety-of-spironolactone-in-patients-with-hfpef-and-chronic-kidney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.